HomeBest options strategy › NUVL

Best Options Strategy for NUVL

By Yojana Mandon · Updated 2026-07-24 · 2 min read · Risk disclaimer

Looking for the best options strategy for Nuvalent, Inc. (NUVL)? There is no single answer — the right play depends on your outlook, your risk tolerance and current implied volatility. Below, our free engine shows the highest-scoring defined-risk strategy on the live NUVL option chain right now, and a simple map from your view on NUVL to the strategy that fits it. Model any of them in the calculator before you trade.

About NUVL

Nuvalent, Inc. (NUVL) is a major company in Biotechnology. Options traders on NUVL tend to watch , since these can drive large moves in the share price.

About Nuvalent, Inc.

Nuvalent is a clinical-stage biopharmaceutical company developing targeted cancer therapies. The company's pipeline centers on three main drug candidates, each designed to overcome common limitations of existing treatments. Zidesamtinib targets ROS1-positive lung cancer and is currently in Phase 2 testing through the ARROS-1 trial, addressing issues like drug resistance, side effects affecting the brain, and brain metastases. Neladalkib, in Phase 2 of the ALKOVE-1 trial, works against ALK-driven cancers with similar goals of improving upon earlier-generation inhibitors. A third candidate, NVL-330, targets HER2-mutant tumors in Phase 1 testing. The company also partners with Guardant Health to develop companion diagnostic tests alongside its drug development efforts.

Nuvalent generates value through advancing its drug candidates through clinical trials toward potential regulatory approval and commercialization. The company's revenue model depends on reaching late-stage development and ultimately bringing these therapies to market, where it would earn sales revenue from patients and healthcare systems. Founded in 2017 and based in Cambridge, Massachusetts, Nuvalent operates in the…

Today's top-scoring strategy for NUVL

Our engine ranks defined-risk strategies on the live NUVL chain by probability of profit and risk/reward, then surfaces the best-scoring one. It is an educational illustration, not advice.

Bull Put Credit Spread bullish
Price: $123.96Implied volatility: 32%Expiration: 2026-08-21 (27d)
ActionQtyTypeStrikePremium
BuyPUT$105$0.15
SellPUT$115$1.16
P/L at expiry vs today At expiry Today ±1σ
$90$114$139
Max Profit
$101
Max Loss
−$899
Net Credit (received)
$101
Breakeven(s)
$113.99
Position Greeks
Δ
15.76
Γ
−1.892
Θ
4.08
ν
−6.95
Time decay (price held)
Implied-volatility skew

Simulation

Forward simulation of 6,000 lognormal price paths to expiration — not a historical backtest.

Win rate
82%
Mean P/L
$4
Median
$101
Exp. move (1σ)
9%
5th pct
−$662
25th pct
$101
75th pct
$101
95th pct
$101

Strategy analysis

Simulated price paths (time × price)
now $124BE $114$107$125$1430d14d27d
$-887$-399$89

Greeks vs price

Δ — $ P/L per $1 move in the underlying (share-equivalent exposure).
Θ — $ P/L per day from time decay.
ν — $ P/L per +1% in implied volatility.
Γ — how fast delta changes per $1 move.

Price × volatility (today)

−30%−15%IV+15%+30%
$155$101$101$101$100$99
$149$101$101$100$99$95
$143$101$100$98$94$86
$136$100$98$91$79$64
$130$95$83$65$43$19
$124$63$32−$1−$34−$65
$118−$58−$101−$139−$170−$196
$112−$325−$340−$353−$363−$372
$105−$647−$617−$594−$576−$562
$99−$842−$810−$779−$750−$726
$93−$894−$884−$869−$851−$831
Analyze NUVL in the calculator → Share this pick ↗

Illustrative example at NUVL's latest available price, computed with the same engine as the tool. Live option fills and the real IV skew refresh during US market hours.

Implied volatility

NUVL is currently trading with moderate implied volatility, broadly in line with other large-cap stocks. On the options we scanned that was around 32% implied volatility, and higher implied volatility means richer premiums and wider expected moves.

Off that volatility, the options market is pricing a move of about ±$10.84 (±9%) in NUVL by 2026-08-21 — a range of roughly $113 to $135. Strikes inside that band hold most of the premium and see most of the action.

Across strikes, downside puts on NUVL trade at a higher implied volatility than upside calls — the market is paying up for crash protection. That skew favours selling put spreads or buying calls over symmetric trades.

NUVL insider trading activity (SEC Form 4)

Open-market insider transactions at NUVL over roughly the last six months, from SEC Form 4 filings. Open-market buys are the rarer, more telling signal — routine selling under pre-arranged plans is common, so read a net-selling figure with that in mind.

Open-market buys
0 · —
Open-market sells
72 · $37.3M
Net (buy − sell)
−$37.3M
InsiderActionSharesValueDate
Pelish Henry E.Sell2,111$261K2026-07-09
Porter James RichardSell30,000$3.7M2026-07-06
Noci DarleneSell23,000$2.8M2026-07-01
Balcom AlexandraSell11,430$1.4M2026-07-01
Noci DarleneSell5,500$679K2026-06-29
Noci DarleneSell20,000$2.5M2026-06-09

Source: SEC Form 4 filings via Finnhub. Open-market purchases (P) and sales (S) only — grants, option exercises, gifts and tax withholding are excluded. Informational context, not investment advice.

Key figures

Market cap
$9.8B
Beta (vs market)
1.14
52-week range
$71.13–$123.99 (100% up the range)
Short interest
6.2% of float · 0.6 days to cover

How to choose an options strategy for NUVL

Start with your outlook on NUVL, then match it to a defined-risk structure. Here are the most common choices and when each makes sense:

Bullish

You expect NUVL to rise

Buy a call for leverage with capped risk, or a bull call spread to lower the cost and breakeven when you have a target price.

Long Call → Bull Call Spread →

Bearish

You expect NUVL to fall

Buy a put to profit from a decline with defined risk, or a bear put spread to cheapen the trade when you expect a measured move down.

Long Put → Bear Put Spread →

Neutral

You expect NUVL to trade in a range

Sell an iron condor to collect premium while NUVL stays between two strikes, or write a covered call against shares you already own.

Iron Condor → Covered Call →

⧉ Embed this free calculator on your site →

How we pick the best strategy

For each ticker we pull the live option chain, build every supported strategy around the at-the-money strikes, and score them on probability of profit, risk/reward and capital efficiency — favouring defined-risk structures where the maximum loss is known up front. Methodology →

Open NUVL in the free calculator →

Frequently asked questions

What is the best options strategy for NUVL?

It depends on your outlook. Bullish traders often use a long call or bull call spread on NUVL; bearish traders a long put or bear put spread; neutral traders an iron condor or covered call. Our live scan above shows the current highest-scoring defined-risk play.

Are NUVL options liquid enough to trade?

Nuvalent, Inc. (NUVL) is among the most actively-traded US options, which usually means tight bid/ask spreads and plenty of strikes and expirations — though you should always check the open interest and spread on the exact contract.

How much money do I need to trade NUVL options?

Buying a single NUVL call or put can cost as little as the premium (often one to a few hundred dollars), while income strategies like a cash-secured put need enough capital to buy 100 shares if assigned.

Is this financial advice?

No. Everything here is educational and uses delayed, third-party data. It is not a recommendation to trade NUVL or any security. Do your own research.

What does Nuvalent, Inc. do?

Nuvalent, Inc. (NUVL) operates in the Biotechnology industry. The "About Nuvalent, Inc." section above gives a fuller picture of what the company does and how it earns money.

Does Nuvalent, Inc. pay a dividend?

We don't show a confirmed dividend yield for Nuvalent, Inc. here, so treat it as uncertain: before writing calls, check its current dividend and ex-dividend date with your broker — an approaching ex-dividend date can trigger early assignment on in-the-money short calls.

Tickers related to NUVL

Comparing NUVL with similar names can help you choose the best options strategy:

PCVXVaxcyte, Inc.CRNXCrinetics Pharmaceuticals, Inc.KYMRKymera Therapeutics, Inc.

Company information

Headquarters
One Broadway, 14th Floor, Cambridge, MA, 02142, United States
Industry
Biotechnology
Employees
234
Phone
857 357 7000
Website
nuvalent.com

Best Options Strategy by Ticker →

Educational use only. Quotes are delayed ~15 minutes and nothing here is financial advice. Options trading involves substantial risk of loss. Privacy · Terms.